NCT06179069

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Efficacy, and Pharmacokinetics in Participants With Small Cell Lung Cancer

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 339 (estimated)
• Sponsor: Zai Lab (Shanghai) Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

An open-label, multicenter study of ZL-1310 as a single agent and in combination with Atezolizumab (with and without Carboplatin) to evaluate the safety, efficacy, and pharmacokinetics in subjects with small cell lung cancer

Detailed description

This is an open-label, ascending, multiple-dose, phase 1 study evaluating ZL-1310 as a single agent, in combination with Atezolizumab, and in combination with Atezolizumab and Carboplatin in subjects with extensive SCLC.

Conditions

• SCLC

Interventions

Type	Name	Description
DRUG	ZL-1310	Drug: ZL-1310
DRUG	Atezolizumab	Drug Atezolizumab
DRUG	Carboplatin	Drug Carboplatin

Timeline

• Start date: 2024-01-23
• Primary completion: 2027-05-30
• Completion: 2027-07-31
• First posted: 2023-12-21
• Last updated: 2026-04-03

Locations

38 sites across 3 countries: United States, China, Spain

Regulatory

• FDA-regulated drug study